Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on April 7, 2016, covering events occurring on April 1 and April 4, 2016. The company is a Nevada corporation focused on robotic exoskeleton technology.

Key Financial Metrics

This filing is a current report regarding specific corporate events and regulatory approvals. It does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.

Material Changes

  • Regulatory Approval: The company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton.
  • Contractual Amendment: The company amended its Securities Purchase Agreement dated December 23, 2015, to clarify that compensatory options granted to employees and directors will not trigger an adjustment to the conversion price of Series A Convertible Preferred Stock or the exercise price of warrants.
  • Corporate Governance: A Certificate of Amendment to the Certificate of Designation for Series A Convertible Preferred Stock was filed to reflect the aforementioned clarification.

Guidance, Outlook, and Risks

Outlook: The FDA clearance allows the company to market the Ekso GT for use in rehabilitation centers for specific patient groups, including individuals with hemiplegia due to stroke and individuals with spinal cord injuries at levels T4 to L5 and T3 to C7 (ASIA D).

Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory context. The amendment to the securities agreement was intended to clarify terms to prevent unintended price adjustments, suggesting a focus on protecting existing investor terms.

Investor Verification Checklist

  • Verify the specific indications for use approved by the FDA for the Ekso GT device as detailed in the device labeling.
  • Review the full text of the Amendment to the Securities Purchase Agreement (Exhibit 10.1) to understand the precise mechanics of the conversion price protection.
  • Confirm the commercialization timeline and strategy for the Ekso GT following the April 2016 clearance.
  • Check subsequent filings for any financial impact or revenue recognition related to the newly cleared device.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.